GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for RESOLVD

RESOLVD

Official Title

Randomized Evaluation of Strategies for Left Ventricular Dysfunction

Status

Completed

Overview

The RESOLVD Pilot Study was a trial of combination neurohormonal blockade using an angiotensin II antagonist (candesartan), an angiotensin-converting enzyme inhibitor (enalapril) and a beta-blocker (metoprolol) in patients with congestive heart failure (CHF).

Study Design

Randomized, two-stage trial consisting of a three-way comparison (stage I), followed by a 3×2 partial factorial design (stage II).

Primary Endpoint

End points included the change in 6MWD, EF, ventricular volumes, neurohormone levels, QOL, and NYHA-FC at weeks 17 or 18 and 43. Tolerance and adverse and clinical events were documented, with serious adverse events reviewed centrally.

Number of Patients

768

Study Period

1996–1998

Principal Investigator

Robert McKelvie, Salim Yusuf

Program Manager

Not Applicable

Research Coordinator

Jackie Bosch

Key Publications

  • Yan RT1, White M, Yan AT, Yusuf S, Rouleau JL, Maggioni AP, Hall C, Latini R, Afzal R, Floras J, Masson S, McKelvie RS; Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Investigators. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol. 2005 Sep 1;96(5):698-704.